Member Info for krautyankee

Statement from Bruce Williams re. appointment of A. Powell: I am pleased to welcome Andrew to Motif Bio’s Board of Directors and very much look forward to working with him. Andrew’s experience in preparing companies for the next phase in their growth, be it through partnering or M&A, will be invaluable as Motif Bio evaluates the MANY opportunities to build on the accomplishments over the last five years.”

The CEO is not allowed to purchase shares as he pleases. A share purchase at this stage (since Feb. massacre) would be tantamount to confirming that the FDA will approve Iclaprim. It would be illegal for him to do this, since he has proprietary information that the rest of us do NOT have. Share purchases by the CEO normally have to be registered & approved by Financial authorities months in advance..

Hey Ivey, I have valued all of your recent input; Question: Would the FDA have issued the CRL if the ONLY issue is indeed related to labeling? Since there was communication back-and-forth during the review process, wouldn't the FDA have told Motif during the review process they would approve the NDA, but with labeling / restrictions? Or is it a mandatory step in the process to issue the CRL and discuss labeling at subsequent meeting? Would the FDA have a subsequent meeting to give Motif the option of approval "now", with labeling, or would Motif prefer to do some kind of small study now, to address concerns, so that the approval could be given in the near-future w/o any labeling? thanks

anyone out there who lives near Motif's offices should borrow a basic hunting scope. This should make it quite easy to determine if the CEO has a smile or a scowl on his face when he leaves work this evening....

from another chat site: "today's RNS re. collaboration is a "strange" move for a drug that supposedly has insurmountable liver toxicity issues"....